LEADER 03620nam 2200961z- 450 001 9910566480103321 005 20231214133332.0 035 $a(CKB)5680000000037579 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/81183 035 $a(EXLCZ)995680000000037579 100 $a20202205d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aRecent Advances in Pancreatic Neoplasms 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 electronic resource (176 p.) 311 $a3-0365-3499-7 311 $a3-0365-3500-4 330 $aPancreatic neoplasms include different pathological entities with variable biological behavior and different treatment modalities. Surgery and adjuvant therapy are the cornerstones of the therapeutic approach; however, even after radical resection, the majority of patients experience disease recurrence and the prognosis of pancreatic cancer remains dismal. A multimodal therapeutic approach, based on a combination of neoadjuvant therapy, chemotherapy, radiotherapy, immunotherapy and surgery, appears fundamental to improving the outcomes. This Special Issue of the Journal of Clinical Medicine, entitled ?Recent Advances in Pancreatic Neoplasms?, focuses on possible new strategies to treat pancreatic neoplasms. 606 $aMedicine$2bicssc 606 $aOncology$2bicssc 610 $aPIWI proteins 610 $aPIWIL3 610 $aPIWIL4 610 $apancreatic cancer 610 $aEMT 610 $achemoresistance 610 $amotility 610 $aHNF4A 610 $asurvival 610 $apancreatic neuroendocrine neoplasm 610 $aprimary pancreatic carcinoid 610 $aserotonin-secreting pancreatic tumour 610 $aserotonin-producing pancreatic tumour 610 $aneoadjuvant chemotherapy 610 $aresponse 610 $acarbohydrate antigen 19-9 610 $afluorodeoxyglucose 610 $apancreatectomy 610 $apositron emission tomography 610 $aprognosis 610 $astandardized uptake value 610 $aPancreatic ductal adenocarcinoma 610 $amicroRNAs 610 $apancreatic fistula 610 $apancreatic neoplasm 610 $arenal cell carcinoma 610 $apancreatic neoplasms 610 $aPET-CT scan 610 $apancreatic ductal adenocarcinoma 610 $apancreatic cancer prognosis 610 $acompletion total pancreatectomy 610 $apooled analysis 610 $arecurrent pancreatic cancer 610 $arepeated pancreatectomy 610 $apancreas 610 $aneuropathy 610 $ataxanes 610 $abiomarker 610 $aC-reactive protein to albumin ratio 610 $ainflammation 610 $aintraductal papillary mucinous neoplasm 610 $amodified Glasgow prognostic score 610 $aneutrophyl lymphocite ratio 610 $aplatelet-to-lymphocyte ratio 610 $arobotic pancreatic surgery 610 $apancreato-gastrostomy 610 $alow muscle mass 610 $asarcopenia 610 $apancreatic adenocarcinoma 610 $apancreatic surgery 610 $abody composition 615 7$aMedicine 615 7$aOncology 700 $aSperti$b Cosimo$4edt$01322431 702 $aSperti$b Cosimo$4oth 906 $aBOOK 912 $a9910566480103321 996 $aRecent Advances in Pancreatic Neoplasms$93034994 997 $aUNINA